{
  "abstract": "Survivin (BIRC5) is broadly overexpressed in human cancers but, as a self-antigen, is subject to immune tolerance that limits spontaneous antitumour immunity. OVM-200 is a recombinant overlapping peptide vaccine spanning full-length survivin, with cathepsin S-cleavable linker sequences inserted between adjacent peptides to enhance antigen processing and presentation. OVM-200-100 was a multicentre, open-label phase 1 study conducted at 4 UK sites. The pooled 2,000-g cohort comprised 27 patients with advanced non-small cell lung, ovarian or prostate cancer, including 24 patients from phase 1b and 3 treated at this dose in phase 1a. OVM-200 was administered subcutaneously every 2 weeks for 3 initial vaccinations, with up to 8 additional doses in patients deriving clinical benefit. The primary endpoint was safety and tolerability, secondary endpoints included survivin-specific immunogenicity, and antitumour activity by RECIST v1.1 was exploratory. OVM-200-related adverse events were exclusively grade 1-2, with no treatment-related grade [≥]3 adverse events, dose-limiting toxicities, serious adverse events or deaths. A systematic literature analysis showed low spontaneous anti-survivin seroreactivity in patients with cancer. In our cohort, pretreatment tumours expressed survivin despite low baseline survivin-specific immunity. OVM-200 vaccination subsequently induced robust humoral and cellular responses, with median anti-survivin IgG titres increasing from 20 at baseline to a peak of 81,920 and median interferon-{gamma} ELISpot responses increasing from 16.7 to 504.6 spot-forming units per 10 PBMCs. Patients receiving [≥]4 vaccinations developed higher anti-survivin antibody titres and stronger T cell responses than those receiving fewer doses. Among 24 RECIST-evaluable patients, the best overall response was stable disease (SD) in 6 patients (25%). Patients with SD had significantly higher anti-survivin antibody titres than those with progressive disease (PD) (p=0.0418). OVM-200 was well tolerated and induced robust survivin-specific immunity, providing clinical evidence that it can break immune tolerance to self-antigen survivin and supporting further development. ClinicalTrials.gov identifier: NCT05104515.",
  "abstract_shown": true,
  "affiliations": [
    "University of Oxford"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "name": "P. K.-T. Wan"
    },
    {
      "name": "T. Morris"
    },
    {
      "name": "M. Forster"
    },
    {
      "name": "T. Zhang"
    },
    {
      "name": "M. Flynn"
    },
    {
      "name": "F. Chamberlain"
    },
    {
      "name": "M. Tuthill"
    },
    {
      "name": "F. Thistlethwaite"
    },
    {
      "name": "A. Williams"
    },
    {
      "name": "W. Finch"
    },
    {
      "name": "W. Lu"
    },
    {
      "affs": [
        0
      ],
      "name": "S. Jiang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e1w0tjpcka1sb.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.11.08.26367556",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.11.08.26367556v1.full",
  "id": "e1w0tjpcka1sb",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.11.08.26367556v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "oncology"
    ]
  ],
  "openalex": null,
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.11.08.26367556v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-08",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/e1w0tjpcka1sb.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T00:21:36Z",
      "native_id": "10.64898/2026.11.08.26367556",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.08.26367556v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:oncology",
      "subfield": "oncology"
    }
  ],
  "title": "OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study",
  "title_text": "OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study",
  "type": "preprint",
  "updated_at": "2026-11-12T00:20:32Z",
  "url": "https://research.draconitic.com/paper/e1w0tjpcka1sb",
  "venue": "medRxiv",
  "versions": []
}